Physician profile

Jonathan Jones

Physician Assistant · Colorado Spgs, CO

NPI 1699003178

$3,246.47

in general payments reported to CMS, 2019-2025

40 companies · $911 in 2025

The $911 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,492.41

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $926.32 2021-2025 Airsupra, Breztri, Farxiga
Abbvie INC. $255.63 2021-2024
Amgen INC. $148.11 2021-2025 Evenity, Prolia, Krystexxa
Pfizer INC. $144.67 2021-2024
Seqirus USA INC $141.93 2023-2025 Flucelvax, Fluad, Fluad Quadrivalent
Vertical Pharmaceuticals, LLC $128.43 2023-2025 Relexxii
Lilly USA, LLC $107.02 2021-2025 Mounjaro, Kisunla
Novo Nordisk INC $104.23 2023-2025 Rybelsus, Ozempic
Bayer Healthcare Pharmaceuticals INC. $96.16 2022-2024
Hologic Sales and Service, LLC $95.85 2022-2025 Aptima, Thinprep 2000 Processor
Glaxosmithkline, LLC. $94.45 2022-2025 Arexvy, Shingrix, Bexsero
Corium, LLC $94.35 2024-2025 Azstarys
Inspire Medical Systems, INC. $85.76 2024 Inspire
Biohaven Pharmaceuticals, INC. $84.44 2021
Biohaven Pharmaceutical Holding Company LTD. $77.84 2022
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Ironshore Pharmaceuticals INC. $75.55 2023-2024 Jornay Pm
Edwards Lifesciences Corporation $64.05 2023-2024 Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Aimmune Therapeutics, INC. $48.33 2025 Zenpep
Exact Sciences Corporation $41.74 2025 Cologuard Collection Kit
Alexion Pharmaceuticals, INC. $39.28 2021-2023 Strensiq
Supernus Pharmaceuticals, INC. $33.37 2023-2024 Qelbree, Qelbree
Merck Sharp & Dohme LLC $27.08 2021-2022
Alkermes, INC. $25.59 2024 Aristada, Lybalvi
Sobi, INC $25.27 2022
Collegium Pharmaceutical, INC. $24.57 2025 Jornay Pm
Cranial Technologies, INC $23.04 2021
Ultragenyx Pharmaceutical INC. $22.13 2022
Boehringer Ingelheim Pharmaceuticals, INC. $21.56 2021
Adlon Therapeutics L.P. $19.92 2021
Otsuka America Pharmaceutical, INC. $19.26 2023 Abilify Maintena, Rexulti
Vertex Pharmaceuticals Incorporated $19.07 2024
Avion Pharmaceuticals $18.89 2023 Methylphenidate Hydrochloride
Heron Therapeutics, INC. $17.35 2025 Aponvie
Horizon Therapeutics Plc $16.90 2023 Krystexxa
Kowa Pharmaceuticals America, INC. $15.43 2023 Livalo
Sanofi Pasteur INC. $14.84 2024
Novartis Pharmaceuticals Corporation $14.32 2022
Idorsia Pharmaceuticals US INC $12.85 2023 Quviviq
Nevro Corp. $11.39 2021
The Binding Site INC. $9.50 2025 Freelite

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jonathan Jones

$3,246.47

in general payments reported 2019-2025

Years
2021-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $911 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).

https://glasscript.com/doctor/10632467/jonathan-jones

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.